BRPI0820387A2 - Agentes de ligação de wise e epítopos - Google Patents

Agentes de ligação de wise e epítopos

Info

Publication number
BRPI0820387A2
BRPI0820387A2 BRPI0820387-3A BRPI0820387A BRPI0820387A2 BR PI0820387 A2 BRPI0820387 A2 BR PI0820387A2 BR PI0820387 A BRPI0820387 A BR PI0820387A BR PI0820387 A2 BRPI0820387 A2 BR PI0820387A2
Authority
BR
Brazil
Prior art keywords
epitopes
binding agents
wise binding
wise
agents
Prior art date
Application number
BRPI0820387-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Xueming Qian
Kevin Graham
Grant Shimamoto
Barbara S Tipton
Mei-Mei Tsai
Aaron George Winters
Li Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0820387A2 publication Critical patent/BRPI0820387A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0820387-3A 2007-11-21 2008-11-21 Agentes de ligação de wise e epítopos BRPI0820387A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21
PCT/US2008/012987 WO2009070243A2 (en) 2007-11-21 2008-11-21 Wise binding agents and epitopes

Publications (1)

Publication Number Publication Date
BRPI0820387A2 true BRPI0820387A2 (pt) 2015-05-26

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820387-3A BRPI0820387A2 (pt) 2007-11-21 2008-11-21 Agentes de ligação de wise e epítopos

Country Status (17)

Country Link
US (2) US8043620B2 (enExample)
EP (1) EP2220118A2 (enExample)
JP (2) JP5583591B2 (enExample)
KR (1) KR20100099193A (enExample)
CN (1) CN101925611A (enExample)
AU (1) AU2008330125B2 (enExample)
BR (1) BRPI0820387A2 (enExample)
CA (1) CA2705879A1 (enExample)
CO (1) CO6311002A2 (enExample)
CR (1) CR11523A (enExample)
EA (1) EA201000844A1 (enExample)
IL (1) IL205569A0 (enExample)
MA (1) MA31918B1 (enExample)
MX (1) MX2010005656A (enExample)
TN (1) TN2010000213A1 (enExample)
WO (1) WO2009070243A2 (enExample)
ZA (1) ZA201003578B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
RS58231B1 (sr) 2005-11-23 2019-03-29 Acceleron Pharma Inc Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR101526613B1 (ko) 2007-02-01 2015-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201808334A (zh) 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE063136T2 (hu) 2008-08-14 2023-12-28 Acceleron Pharma Inc GDF-Csapdák
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CA2818237C (en) 2009-11-18 2021-05-18 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CN102770456B (zh) * 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
NZ602734A (en) * 2010-03-02 2014-10-31 Abbvie Inc Therapeutic dll4 binding proteins
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
WO2013082463A2 (en) * 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-fu
TW201333040A (zh) * 2012-01-06 2013-08-16 Bioalliance Cv 抗－輸鐵蛋白受器之抗體及其使用方法
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
CA2887037A1 (en) * 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activated matriptase
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
RU2670943C9 (ru) * 2012-11-08 2018-11-26 Илэвэн Байотерапьютикс, Инк. Антагонисты ил-6 и их применение
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
EP3041869A1 (en) 2013-09-05 2016-07-13 Duke University Nav1.7 antibodies and methods of using the same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
IL252631B2 (en) 2014-12-03 2024-06-01 Celgene Corp ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
AR107708A1 (es) 2016-02-23 2018-05-23 Eleven Biotherapeutics Inc Formulaciones de antagonista de il-6 y sus usos
CA3017958C (en) 2016-03-18 2024-03-12 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7128191B2 (ja) * 2017-01-06 2022-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療抗ＩｇＥ抗体並びにその方法及び組成物
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
JP7572668B2 (ja) * 2019-07-12 2024-10-24 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
EP4466291A4 (en) 2022-01-28 2025-07-16 Georgiamune Inc ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1, PD-1 AGONISTS
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
EP2144613B1 (en) * 2006-12-29 2018-03-21 OstéoQC Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
CN104945508B (zh) * 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR101471239B1 (ko) * 2009-05-12 2014-12-09 화이자 인코포레이티드 항-ｄｋｋ-1 항체의 차단 및 그의 용도

Also Published As

Publication number Publication date
CR11523A (es) 2010-12-16
MA31918B1 (fr) 2010-12-01
EP2220118A2 (en) 2010-08-25
AU2008330125B2 (en) 2012-11-22
CN101925611A (zh) 2010-12-22
CA2705879A1 (en) 2009-06-04
TN2010000213A1 (en) 2011-11-11
US8043620B2 (en) 2011-10-25
WO2009070243A3 (en) 2009-10-29
JP2011504501A (ja) 2011-02-10
US8309092B2 (en) 2012-11-13
MX2010005656A (es) 2010-11-12
JP2014167002A (ja) 2014-09-11
US20120003237A1 (en) 2012-01-05
ZA201003578B (en) 2011-04-28
WO2009070243A2 (en) 2009-06-04
EA201000844A1 (ru) 2011-10-31
CO6311002A2 (es) 2011-08-22
US20090130114A1 (en) 2009-05-21
AU2008330125A1 (en) 2009-06-04
KR20100099193A (ko) 2010-09-10
IL205569A0 (en) 2010-12-30
JP5583591B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
BRPI0820387A2 (pt) Agentes de ligação de wise e epítopos
CY2020009I2 (el) Δεσμευτικοι παραγοντες σκληροστινης
PT2173888T (pt) Resumo
ATE543405T1 (de) Frisiergerät
ATE443753T1 (de) Nuancierungsmittel
DK2178568T3 (da) Kontrastmidler
BRPI0807137A2 (pt) Agentes antiparasitários
EP3241842C0 (en) PRESENTATION OF LIAISON AGENTS
EP2155121A4 (en) INTERSPINED DISTANCE MEMBER
DE602006021235D1 (de) Kristallglasgegenstand
EP2215246A4 (en) PROTEIN SCAFFOLDS
HRP20170963T1 (hr) Modificirani saharidi
BRPI0806964A2 (pt) Combinações de agonístico beta-2-adrenoceptor e benzotiazolona
EP2117452A4 (en) TROCHANTARY HANDLE
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
FI7098U1 (fi) Kaidejärjestelmä
BRPI0818697A2 (pt) Depilador
EP2214719A4 (en) Metallofullerene-DYE
EP2197447A4 (en) ANTIFUNGALS
EP2217071A4 (en) ANTIMYCOTIC AGENTS
BRPI0807603A2 (pt) Composição depilatóra
EP2202304A4 (en) MODIFIED CREATININE AMIDOHYDROLASE
FI20050547A0 (fi) Side
FR2901185B1 (fr) Ouvrant arriere renforce
FI20070466A0 (fi) Sidontalaite

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.